Myofascialpainandtreatment:Editorial

Myofascial pain syndrome (MPS) and its characteristic trigger points (TrPs) remain challenging clinical conditions despite decades of research. A major limitation has been the lack of a reliable animal model for studying TrP pathophysiology. Additionally, diagnosis of MPS relies heavily on clinical examination with ongoing debates about reliability and validity of diagnostic criteria. Treatment options including dry needling, manual therapy, and various physical modalities continue to be investigated, but the evidence base remains fragmented with many studies suffering from methodological limitations.

This editorial provides a comprehensive overview of recent research developments across basic science, diagnostic methods, and treatment interventions for myofascial pain.

This editorial reviewed and summarized approximately 20 recent studies published in the preceding year, organized into five categories: basic research, reviews and meta-analyses, dry needling/acupuncture/injections, manual therapy, and other clinical studies. The authors provided critical commentary on each study's methodology, findings, and limitations. Key studies included: Margalef et al.'s development of the first viable animal model of TrPs using anticholinesterase agents in rodents; Mayoral Del Moral et al.'s examination of inter-examiner reliability for MPS diagnosis; Sollmann et al.'s quantitative MRI-based T2 mapping for TrP identification; multiple systematic reviews on dry needling and manual therapy; and various randomized controlled trials, case reports, and pilot studies examining interventions for myofascial pain in different body regions and patient populations.

The editorial highlighted several significant findings. Margalef et al. successfully created TrPs in rodents using neostigmine, producing palpable taut bands, contraction knots, and local twitch responses. They also identified glycosaminoglycans (GAGs) near TrPs, suggesting these molecules may contribute to TrP formation and palpable nodules. Mayoral Del Moral et al. demonstrated very good inter-examiner reliability for identifying MPS and specific affected muscles.

Sollmann et al. showed that T2 mapping could identify TrPs even without qualitative signal alterations on conventional MRI. For treatments, the meta-analysis by Hu et al. found dry needling superior to sham for low back pain, while Denneny et al.'s review of manual therapy found no consistent evidence for pain reduction with ischemic compression alone. Mansfield et al. found little evidence that needling affects muscle force production. Several studies examined dry needling for specific conditions: Arias-Buría et al. found cost-effectiveness benefits when adding TrP-DN to exercise for subacromial pain syndrome; Aydin et al. found exercise plus DN superior to exercise alone for cervical myofascial pain with dizziness; and Kamali et al. found both DN and friction massage effective for tension-type headaches.

Manual therapy studies showed mixed results, with some demonstrating immediate benefits but lacking long-term follow-up or adequate controls.

For clinicians, this editorial underscores that myofascial pain diagnosis and treatment remain evolving fields. The development of a reliable animal model represents a significant breakthrough that may accelerate understanding of TrP pathophysiology. The identification of GAGs near TrPs opens new avenues for research into mechanisms and potential therapeutic targets. Clinicians can have increased confidence in clinical examination for MPS diagnosis based on improved reliability data.

For treatment, dry needling continues to accumulate supportive evidence for various conditions, though high-quality RCTs with adequate follow-up remain needed. The editorial cautions against relying on ischemic compression alone as standalone treatment, emphasizing that multimodal approaches are likely more effective. The lack of consistent evidence for needling's effects on muscle force production suggests this should not be a primary treatment goal. For patients, this overview suggests that while various treatments show promise, individual responses vary and treatment selection should be tailored to specific presentations.

The editorial repeatedly calls for better-designed studies with larger samples, longer follow-up periods, and appropriate control groups to strengthen the evidence base for clinical decision-making.